Design, Synthesis and Investigation of New Diphenyl Substituted Pyridazinone Derivatives as Both Cholinesterase and Aβ-Aggregation Inhibitors

Author(s): Burcu Kilic, Merve Erdogan, Hayrettin O. Gulcan, Fatma Aksakal, Nihan Oruklu, Emin U. Bagriacik, Deniz S. Dogruer*.

Journal Name: Medicinal Chemistry

Volume 15 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: With respect to the increase in the average life expectancy, Alzheimer Disease (AD), the most common form of age-related dementia, has become a major threat to the population over the age of 65 during the past several decades. The majority of AD treatments are focused on cholinergic and amyloid hypotheses.

Objective: In this study, three series of diphenyl-2-(2-(4-substitutedpiperazin-1-yl)ethyl)pyridazin- 3(2H)-one derivatives were designed, synthesized and investigated for their ability to inhibit both cholinesterase enzymes and amyloid-β aggregation.

Method: The inhibitory activities of the synthesized compounds on AChE (from electric eel) and BChE (from equine serum) were determined by the modified Ellman’s method. The reported thioflavin T-based fluorometric assay was performed to investigate the effect of the selected compounds on the aggregation of Aβ1-42. The cytotoxic effect of the compounds (4g, 11g and 18g) was monitored in 3T3 cell lines to gain insight into therapeutic potential of the compounds by using MTT assay. The crystal structures of the AChE (1EVE) and BChE (1P0I) enzymes were retrieved from the RCSB Protein Data Bank and Molecular Operating Environment (MOE) software was used for molecular docking of the ligands.

Results: Among the tested compounds, 5,6-diphenyl derivative 18g was identified as the most potent and selective AChE inhibitor (IC50 = 1.75 µM, Selectivity Index for AChE > 22.857). 4,6- Diphenyl derivative 11g showed the highest and the most selectivity for BChE (IC50= 4.97 µM, SI for AChE < 0.124). Interestingly, 4,5-diphenyl derivative 4g presented dual cholinesterase inhibition (AChE IC50= 5.11 µM; BChE IC50= 14.16 µM, SI for AChE = 2.771).

Conclusion: Based on biological activity results and low toxicity of the compounds, it can be said that diphenyl substituted pyridazinone core is a valuable scaffold. Especially, dual inhibitory potencies of 4,5-diphenylpyridazin-3(2H)-one core for the cholinesterase enzymes and Aβ- aggregation makes this core a promising disease-modifying agent.

Keywords: Alzheimer's disease, pyridazinone, acetylcholinesterase inhibitory activity, butyrylcholinesterase inhibitory activity, molecular docking, rational drug design.

[1]
Martin, P.; Anders, W.; Maëlenn, G.; Gemma, C.A.; Yu Tzu, W.; Matthew, P. World Alzheimer Report 2015 The Global Impact of Dementia An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer’s Disease International; Alzheimer's Disease International: London, 2015, pp. 1-82.
[2]
Qiu, C.; Kivipelto, M.; von Strauss, E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci., 2009, 11(2), 111-128.
[3]
Armstrong, R.A. What causes alzheimer’s disease? Folia Neuropathol., 2013, 3, 169-188.
[4]
Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2011, 1(1), a006189.
[5]
Kumar, A.; Singh, A. Ekavali A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol. Rep., 2015, 67(2), 195-203.
[6]
Anand, R.; Gill, K.D.; Mahdi, A.A. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology, 2014, 76Pt A, 27-50.
[7]
Unzeta, M.; Esteban, G.; Bolea, I.; Fogel, W.A.; Ramsay, R.R.; Youdim, M.B.H.; Tipton, K.F.; Marco-Contelles, J. Multi-target directed donepezil-like ligands for alzheimer’s disease. Front. Neurosci., 2016, 10, 205.
[8]
Prati, F.; Cavalli, A.; Bolognesi, M.L. Navigating the chemical space of multitarget-directed ligands: From hybrids to fragments in Alzheimer’s disease. Molecules, 2016, 21(4), 466.
[9]
Guzior, N.; Wieckowska, A.; Panek, D.; Malawska, B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr. Med. Chem., 2015, 22(3), 373-404.
[10]
Giacobini, E. selective inhibitors of butyrylcholinesterase a valid alternative for therapy of alzheimer’s disease? Drugs Aging, 2001, 18(21), 891-898.
[11]
Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4(2), 131-138.
[12]
Inestrosa, N.; Alvarez, A.; Moreno, R.; Vicente, M.; Linker, C.; Casanueva, O.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
[13]
Munoz-Ruiz, P.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millan, M.; Valenzuela, R.; Usan, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Medina, M.; Martinez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer’s disease. J. Med. Chem., 2005, 48(23), 7223-7233.
[14]
Gazit, E. Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool. FEBS J., 2005, 272(23), 5971-5978.
[15]
Reinke, A.A.; Gestwicki, J.E. Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility. Chem. Biol. Drug Des., 2007, 70(3), 206-215.
[16]
Sakono, M.; Zako, T. Amyloid oligomers: formation and toxicity of Aβ oligomers. FEBS J., 2010, 277(6), 1348-1358.
[17]
Kılıc, B.; Gulcan, H.O.; Yalcın, M.; Aksakal, F.; Dimoglo, A.; Sahin, M.F.; Dogruer, D.S. Synthesis of Some New 1 (2H)-Phthalazinone Derivatives and Evaluation of Their Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activities. Lett. Drug Des. Discov., 2017, 14(2), 159-166.
[18]
Saxena, A.; Fedorko, J.M.; Vinayaka, C.R.; Medhekar, R.; Radic, Z.; Taylor, P.; Lockridge, O.; Doctor, B.P. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (AriceptR) to cholinesterases. Eur. J. Biochem., 2003, 270(22), 4447-4458.
[19]
Yamali, C.; Gulcan, H.O.; Kahya, B.; Cobanoglu, S.; Sukuroglu, M.K.; Dogruer, D.S. Synthesis of some 3(2H)-pyridazinone and 1(2H)-phthalazinone derivatives incorporating aminothiazole moiety and investigation of their antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitory activities. Med. Chem. Res., 2015, 24(3), 1210-1217.
[20]
Sotelo, E.; Coelho, A.; Raviña, E. Pyridazines. Part 34: Retro-ene-assisted palladium-catalyzed synthesis of 4,5-disubstituted-3(2H)-pyridazinones. Tetrahedron Lett., 2003, 44(24), 4459-4462.
[21]
Kavitha, N.; Divekar, K.; Priyadarshini, B.; Gajanan, S.; Manjunath, M. Synthesis and antimicrobial activities of some new pyrazole derivatives. Der. Pharma. Chemica, 2011, 3(4), 55-62.
[22]
Allen, C.F.H.; Kimball, R.K. α-Phenyl-β-Benzoylpropionitrile. Org. Synth., 1930, 10, 80.
[23]
Coudert, P.; Couquelet, J.; Tronche, P. A New Synthetic Route to 4,6-Diarylpyridazinones and Some of their Derivatives. J. Heterocycl. Chem., 1988, 25.
[24]
Allen, C.F.H.; Barker, W.E. Desoxybenzoin. Org. Synth. 1932, 16-16.
[25]
Ranade, A.C.; Mali, R.S.; Kurnawal, V.M. An Unusual Reaction of A Phosphorane With Benzoins: Formation of 1, 2‐Dicarbonyl and 1,4‐Dicarbonyl Compounds. Indian J. Chem., 1984, 23B, 514-517.
[26]
Taylor, H.M.; Hauser, C.R. Conjugate addition of α-Dimethyl-aminophenylacetonitrile with Benzalacetophenone and Ethyl Cinnamate by Means of Potassium Amide. J. Am. Chem. Soc., 1960, 82(7), 1790-1792.
[27]
Baddar, F.G.; El-Habashi, A.; Fateen, A.K. Pyridazines. Part II. The action of grignard reagents on 6-aryl-2, 3, 4, 5-tetrahydro-and-2, 3-dihydropyridazin-3-ones. J. Chem. Soc., 1965, 3342-3348.
[28]
Mohamed, T.; Zhao, X.; Habib, L.K.; Yang, J.; Rao, P.P. Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Abeta-aggregation inhibitors. Bioorg. Med. Chem., 2011, 19(7), 2269-2281.
[29]
Bolognesi, M.L.; Andrisano, V.; Bartolini, M.; Banzi, R.; Melchiorre, C. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. J. Med. Chem., 2005, 48(1), 24-27.
[30]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[31]
Molinspiration. Molinspiration Cheminformatics Nova ulica SK- 900 26 Slovensky Grob Slovak Republic
[32]
Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, P.W.; Tang, Y. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model., 2012, 52(11), 3099-3105.
[33]
Kryger, G.; Silman, I.; Sussman, J. Structure of acetylcholinesterase complexed with E2020 (Aricep): implications for the design of new anti-Alzheimer drugs. Structure, 1999, 7(3), 297-307.
[34]
Ellman, G.L.; Courtney, K.D.; Andres, V.; Feather-Stone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
[35]
Obregon, A.D.C.; Schetinger, M.R.C.; Correa, M.M.; Morsch, V.M.; Silva, J.E.P.; Martins, M.A.P.; Bonacorso, H.G.; Zanatta, N. Effects per se of organic solvents in the cerebral acetylcholinesterase of rats. Neurochem. Res., 2005, 30(3), 379-384.
[36]
Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J.C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem., 2003, 278(42), 41141-41147.
[37]
Molecular Operating Environment (MOE), C.C.G.I., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 2015.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [59 - 76]
Pages: 18
DOI: 10.2174/1573406414666180524073241
Price: $58

Article Metrics

PDF: 29
HTML: 3